Home » Newsletters » BioWorld Science

BioWorld Science

March 22, 2022

View Archived Issues

Researchers discover genetic targets linking endometriosis, ovarian cancer subtypes

PKMYT1 inhibitor RP-6306 for the treatment of aberrant DNA damage repair-driven cancers

Chongqing Medical University compounds inhibit GST isozyme Mu, sensitize tumors to cisplatin in vivo

The role of DNA-PKcs and Fis1 in acute kidney injury pathogenesis

Hangzhou Bangshun Pharmaceutical discloses ROCK2 inhibitors

Targeting HIF-1alpha/CXCR4 axis as therapeutic strategy in ESCC

ASK1 inhibition for the treatment of neuroinflammation, stroke and ALS

Targeting ART1 improves tumor control in NSCLC

In vivo data show Evusheld retains neutralizing activity against Omicron SARS-CoV-2 BA.2 subvariant

RNAGene and PharmAbcine collaborate to develop next-generation mRNA-based antibody therapeutics

IRLAB to advance IRL-757 for apathy in neurodegenerative disorders

Chimeron to use NIAID preclinical services program for COVID-19 vaccine candidate

iTolerance raises financing to advance preclinical programs based on iTOL-100 platform technology

Philochem and Bracco Imaging collaborate on small molecule for imaging applications

AU-007 shows promising anticancer activity in murine models

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 15, 2026.
Microbiota modulates the antidepressant effects of GLP-1 analogues
BioWorld Science
Liraglutide, a glucagon-like peptide 1 (GLP-1) receptor agonist used in diabetes and obesity, could alleviate depression through a pathway that does not depend on...
Ethyreal launches to treat the underlying cause of Graves’, TED
BioWorld
Ethyreal Bio Inc. has come out of stealth mode in order to disclose preclinical data for ETHY-001, its monoclonal antibody targeting thyroid stimulating hormone...
EHA 2026: With new lenses, a changing view on pediatric cancers
BioWorld
In the most simplistic view, adult cancers occur because “immature cells are exposed to mutagens, accumulate mutations, and across life ultimately transform into...
Enliven’s phase I CML data Enable phase III with BCR/ABL1 bid
BioWorld
Tolerability is a key factor in the appeal of Enliven Therapeutics Inc.’s ELVN-001 for previously treated chronic myeloid leukemia (CML), which yielded positive...